Lactobacillus gasseri, composition containing lactobacillus gasseri and imidazole dipeptide and related application

Abstract

The invention provides lactobacillus gasseri, a composition containing the lactobacillus gasseri and imidazole dipeptide and related application. Specifically, the invention provides the lactobacillus gasseri, and the preservation number of the lactobacillus gasseri is CCTCC (China Center for Type Culture Collection) NO: M 20241476. The lactobacillus gasseri can stimulate intestinal pheochromophilic cells to generate 5-HTP, and the lactobacillus gasseri and imidazole dipeptide are combined to achieve the remarkable effects of helping sleep and relieving nervous tension and can be applied to preparation of food and / or food additives.

Description

Technical Field

[0001] The present invention relates to a Lactobacillus gasseri and its applications. Specifically, it relates to a Lactobacillus gasseri that helps with sleep and relieves nervous tension, a composition containing this bacterium and imidazole dipeptide, and their applications in preparing foods and / or food additives. Background Art

[0002] Insomnia is a common health problem in modern society, affecting hundreds of millions of people globally. Chronic insomnia not only affects an individual's daily life and work efficiency but may also trigger a series of health problems such as cardiovascular diseases, diabetes, etc. Currently, the treatment methods for insomnia include drug therapy, psychotherapy, etc., but these methods often have problems such as dependence, side effects, or short-lived effects.

[0003] Food, as a natural means of promoting sleep, is increasingly favored by people. Some food ingredients such as magnesium, tryptophan, γ-aminobutyric acid (GABA), and melatonin have been proven to have sleep-promoting effects through research.

[0004] γ-aminobutyric acid (GABA) is a natural non-protein amino acid widely present in the human body and plants. As the main inhibitory neurotransmitter, it plays an important role in regulating nervous system activities, relieving stress, and promoting sleep. In the food field, GABA is usually added to various foods and beverages such as tea drinks, chocolates, biscuits, etc., in the hope of helping people improve sleep quality by consuming these GABA-containing foods. However, there are differences in the absorption and response of different individuals to GABA, and some people may not experience the expected sleep-promoting effect. Moreover, long-term consumption of GABA can lead to tolerance in people.

[0005] Melatonin is usually used as an oral supplement to adjust the sleep cycle and improve sleep quality. It mimics the melatonin naturally secreted by the human body and helps regulate the sleep-wake cycle, especially for those who experience sleep problems due to jet lag, night shift work, or sleep disorders. Melatonin supplements may cause some side effects such as headache, nausea, drowsiness, abnormal dreams, etc. Long-term or excessive use of melatonin may lead to the body's dependence on the drug and reduce the secretion of its own melatonin. There are differences in the response of different individuals to melatonin, and some people may be insensitive to the supplement or have limited effects. Melatonin may interact with other drugs (such as anticoagulant drugs, immunosuppressive drugs, etc.), affecting the drug efficacy or increasing the risk of side effects.

[0006] Currently, all existing technologies will have side effects such as tolerance and dependence, and the products cannot completely cure the insomnia problem. There is a need to study an edible composition that can improve the intestinal ecology as a means through the gut-brain axis circuit, enabling the body to solve insomnia, high stress, etc. problems endogenously. Summary of the Invention

[0007] In the research, the inventors of this case found a strain of Lactobacillus gasseri isolated from Indonesian tempeh ferment. In this invention, this strain is numbered LyLG1, which can stimulate enterochromaffin cells to produce 5-HTP, has an inhibitory effect on MAO-A enzyme, especially has a synergistic effect when combined with imidodipeptide, and can be applied to the preparation of food and / or food additives.

[0008] The strain LyLG1 of this invention has been deposited with the China Center for Type Culture Collection (CCTCC) (address of the depositary institution: Wuhan University, Wuhan, China, postal code: 430072), deposit date: July 3, 2024; deposit number: CCTCC NO: M 20241476; taxonomic name: Lactobacillus gasseri.

[0009] On the one hand, this invention provides Lactobacillus gasseri with deposit number CCTCC NO: M 20241476.

[0010] On the other hand, this invention also provides a bacterial preparation containing the Lactobacillus gasseri described in this invention.

[0011] According to the specific implementation plan of this invention, the bacterial preparation described in this invention is a liquid or solid preparation in live or inactivated form.

[0012] According to the specific implementation plan of this invention, in the bacterial preparation described in this invention, in addition to the Lactobacillus gasseri, appropriate excipients can also be included, which can be common excipients in lactobacillus preparations.

[0013] According to the specific implementation plan of this invention, in the bacterial preparation described in this invention, in addition to the Lactobacillus gasseri, prebiotics can also be further included, such as one or more of raffinose oligosaccharides, chitosan oligosaccharides, inulin, etc.

[0014] According to the specific implementation plan of this invention, the viable bacteria concentration of the solid preparation of viable bacteria described in this invention is 5×10 11 to 4×10 12 CFU / g, and the viable bacteria concentration of the liquid preparation of viable bacteria is 5×10 11 to 4×10 12 CFU / mL.

[0015] On the other hand, this invention also provides a postbiotic, which is a postbiotic containing bacterial cells and metabolites obtained by fermenting and culturing the Lactobacillus gasseri or the bacterial preparation described in this invention in a culture medium, or a postbiotic containing fermentation products.

[0016] According to specific embodiments of the present invention, the culture medium can be a traditional Lactobacillus culture medium, for example, it can be a peptone medium or an MRS medium.

[0017] In some specific embodiments of the present invention, the composition of the culture medium includes: lactose 38 g / L, soy peptone 62.66 g / L, tryptone 31.33 g / L, dipotassium hydrogen phosphate 5.75 g / L, anhydrous sodium acetate 14.27 g / L, sodium citrate 5.75 g / L, FeSO4·7H2O 0.01 g / L, Tween-80 1 g / L.

[0018] According to specific embodiments of the present invention, the fermentation product obtained by fermenting and culturing the Lactobacillus gasseri in the culture medium is postbiotic containing bacteria and metabolites; alternatively, the fermentation product is further centrifuged to collect the supernatant of the fermentation broth and filtered through a filter membrane to obtain postbiotic containing metabolites without bacteria; optionally, the postbiotic can be further dried to prepare a powder.

[0019] On the other hand, the present invention also provides a composition, which contains the Lactobacillus gasseri, the bacterial preparation or the postbiotic described in the present invention, and also contains imidazole dipeptide.

[0020] According to specific embodiments of the present invention, in the composition of the present invention, the ratio of the Lactobacillus gasseri, the bacterial preparation or the postbiotic to imidazole dipeptide is: Lactobacillus gasseri 2 - 3 parts by weight: imidazole dipeptide 0.05 - 0.6 parts by weight.

[0021] According to specific embodiments of the present invention, in the composition of the present invention, the imidazole dipeptide includes anserine and carnosine. Preferably, the ratio of anserine to carnosine is 5 - 40:0.5 - 20.

[0022] According to specific embodiments of the present invention, the raw materials providing the imidazole dipeptide can be commercially obtained, and can be high-purity anserine raw materials and carnosine raw materials, or food-grade raw materials rich in anserine and carnosine. Generally, in food-grade raw materials rich in anserine and carnosine, the content of the active ingredient (imidazole dipeptide) is 5% - 60%. Such food-grade raw materials are usually prepared from animal meats (such as chicken, fish, etc.), in which the anserine content is about 5% - 40%, the carnosine content is about 0.5% - 20%. In addition to anserine and carnosine, the remaining components are mainly carbohydrates, and also contain a small amount of meat-derived proteins not removed during the production process, as well as a small amount of ash and moisture. Unless otherwise specified, the specific dosage and ratio of the imidazole dipeptide described in the present invention are calculated based on the amount of the active ingredient in the raw materials.

[0023] According to a specific embodiment of the present invention, in the composition of the present invention, in addition to the Lactobacillus gasseri and imidazole dipeptide, an appropriate amount of excipients may be further included as needed.

[0024] On the other hand, the present invention also provides the use of the Lactobacillus gasseri, the bacterial preparation, the postbiotic, or the composition in the preparation of food and / or food additives.

[0025] According to a specific embodiment of the present invention, in the present invention, the food may be one or more of powder solid beverages, liquid beverages, jellies, chewable tablets, yogurts, baked foods, and capsules.

[0026] According to a specific embodiment of the present invention, the food of the present invention is a health food.

[0027] According to a specific embodiment of the present invention, in the present invention, the food has the efficacy of improving sleep and / or relieving nervous tension.

[0028] On the other hand, the present invention also provides the use of the Lactobacillus gasseri, the bacterial preparation, the postbiotic, or the composition in the preparation of a preparation for stimulating enterochromaffin cells to produce 5-HTP.

[0029] On the other hand, the present invention also provides the use of the Lactobacillus gasseri, the bacterial preparation, the postbiotic, or the composition in the preparation of an MAO-A enzyme inhibitor.

[0030] In summary, the present invention provides the Lactobacillus gasseri strain LyLG1, which can stimulate enterochromaffin cells to produce 5-HTP, has an inhibitory effect on MAO-A enzyme, and especially has a synergistic effect when combined with imidazole dipeptide, and can be applied to the preparation of food and / or food additives. Description of the Drawings

[0031] Figure 1 Showing the stimulation of different strains on the secretion of 5-HTP by the enterochromaffin cell model.

[0032] Figure 2 Showing the inhibition rate of different strains of fermentation supernatants on MAO-A.

[0033] Figure 3 It is a typical graph of the movement trajectory of zebrafish after sample treatment. Note: The black line is the slow movement distance, the green line is the medium movement distance, and the red line is the fast movement distance.

[0034] Figure 4 Showing the awakening activity of zebrafish after sample treatment. Compared with the model control group, **p<0.01, ***p<0.001.

[0035] Figure 5Show the MAO-A enzyme inhibition rate of the bacteriocin composition and other component raw materials.

[0036] Microbial preservation for patent procedures:

[0037] Lactobacillus gasseri LyLG1:

[0038] Date of deposit: July 3, 2024;

[0039] Depositary institution: China Center for Type Culture Collection (CCTCC);

[0040] Address of the depositary institution: Wuhan University, Wuhan, China, Zip Code: 430072;

[0041] Deposit number: CCTCC NO: M 20241476;

[0042] Taxonomic name: Lactobacillus gasseri. Detailed implementation manners

[0043] Before further describing the specific implementation manners of the present invention, it should be understood that the protection scope of the present invention is not limited to the following specific implementation manners; it should also be understood that the terms used in the embodiments of the present invention are for describing specific implementation manners and not for limiting the protection scope of the present invention.

[0044] When the embodiments give a numerical range, it should be understood that unless otherwise specified in the present invention, any value between the two endpoints of each numerical range and any value between the two endpoints can be selected.

[0045] Unless otherwise defined, all technical and scientific terms used in the present invention have the same meaning as commonly understood by those skilled in the art of this technology.

[0046] Except for the specific methods, equipment, and reagent materials used in the embodiments, according to the knowledge of those skilled in the art of this technology and the description of the present invention, any methods, equipment, and materials of the prior art similar to or equivalent to the methods, equipment, and reagent materials described in the embodiments of the present invention can also be used to implement the present invention.

[0047] Unless otherwise specified, the experimental methods, detection methods, and preparation methods disclosed in the present invention all adopt the conventional techniques in the art of this technology.

[0048] To make the present invention easier to understand, certain technical and scientific terms are specifically defined below. Unless otherwise clearly defined in this article, all other technical and scientific terms used in this article have the meanings commonly understood by those skilled in the art.

[0049] In this specification, the "some specific / preferred embodiments", "other specific / preferred embodiments", "embodiments", "implementation manners", etc. mentioned refer to the specific elements (e.g., features, structures, properties, and / or characteristics) related to the embodiment / implementation manner, which are included in at least one of the embodiments described herein, and may or may not exist in other embodiments. Additionally, it should be understood that the elements can be combined in various embodiments in any suitable manner.

[0050] In each example, the bacteriopeptide composition (referred to as the composition for short) is a composition comprising Lactobacillus gasseri and imidodipeptide. The raw material providing the imidodipeptide is a food-grade imidodipeptide composition raw material derived from fish. In this raw material, the content of anserine is about 10%, the content of carnosine is about 1%, the remaining components are mainly carbohydrates, and in addition, it also contains a small amount of protein derived from fish that has not been removed during the production process, as well as a small amount of ash and moisture.

[0051] Example 1: Screening and identification of Lactobacillus gasseri

[0052] After diluting the fermentation broth of Indonesian tempeh, it was spread on a plate. After culturing for 24 hours, a plate with a moderate density was selected, and a single colony was picked for streak purification, and the purified strain was preserved.

[0053] A strain of Lactobacillus gasseri was found among the above-separated strains, named LyLG1 in the present invention. The strain LyLG1 of the present invention has been deposited in the China Center for Type Culture Collection (CCTCC) (Depositary address: Wuhan University, Wuhan, China, Zip code: 430072), Deposit date: July 3, 2024; Deposit number: CCTCC NO: M 20241476; Taxonomic name: Lactobacillus gasseri. After detection, this strain is a viable strain.

[0054] Identification of the LyLG1 strain of the present invention:

[0055] rRNA sequence of Lactobacillus gasseri (SEQ ID NO.1):

[0056]

[0057] When the strain LyLG1 of the present invention is cultured in MRS culture medium, the bacterial cells are short rod-shaped, round at both ends, usually appear alone or in pairs of short chains. Gram staining: positive; flagella: none; spore formation: none.

[0058] Cultivation conditions: Use MRS medium (which can be obtained commercially, for example, it can be purchased from Beijing Land Bridge, product number CM188). Dissolve 64.25 g of the medium in 1 L of distilled water, heat to boiling until completely dissolved, autoclave at 121 °C for 15 minutes, and after cooling, pour Lactobacillus gasseri preserved in purified form into the medium for cultivation. The cultivation temperature is 37 °C, facultative anaerobic.

[0059] Example 2: Lactobacillus gasseri stimulates the secretion of 5-HTP by the enterochromaffin cell model

[0060] The use of selective serotonin reuptake inhibitors that can increase the concentration of 5-HT in the body is a drug widely used to treat depression, anxiety and other mental health problems. The stimulating effect on the secretion of 5-HTP by the enterochromaffin cell model. And 5-HTP can cross the blood-brain barrier and be converted into 5-HT in the brain.

[0061] After each strain was co-cultured with the cell model for 1 hour, the content of 5-HTP in its supernatant was detected.

[0062] Among them, the Lactobacillus strains Ly11 (Lacticaseibacillus paracasei strain R094), LT12 (Lacticaseibacillus paracasei strain LT12, BCRC910461), Ly17 (Limosilactobacillus fermentum strain CIP 102980), LyFD (Lactobacillus reuteri), LyLF (Lactobacillus fermentum) and LyT1 (Lactobacillus fermentum) were all provided by Li Tong Co., Ltd. and are available to the public.

[0063] Cell culture: RIN14B cells are cultured in RPMI1640 medium containing 10% FBS at 37 °C and 5% CO2.

[0064] Bacterial stimulation: The bacteria are cultured until the late logarithmic growth phase, and the concentration is adjusted to 10 8CFU / mL. The bacterial supernatant was co-incubated with RIN14B cells for 1 hour. Hank's Balanced Salt Solution (HBSS) was co-incubated with RIN14B cells as a blank control group. The cell supernatant was collected for 5-HTP / 5-HT determination.

[0065] 5-HTP / 5-HT determination: It was determined by high performance liquid chromatography-fluorescence detection method (HPLC-FLR). The cell supernatant was diluted with 5% perchloric acid at a ratio of 1:1, and the proteins were precipitated and then filtered. Chromatographic separation was performed using a C18 column, and the fluorescence detection wavelengths were 330 nm (emission) and 290 nm (excitation).

[0066] The results are shown in Figure 1 , and it was found that Lactobacillus gasseri LyLG1 could effectively stimulate the secretion of 5-HTP by the enterochromaffin cell model.

[0067] Example 3: Inhibition of MAO-A by the fermentation supernatant of Lactobacillus gasseri

[0068] MAO-A (Monoamine Oxidase A Gene (warrior Gene)) inhibitors are mainly used to treat depression and anxiety disorders. By inhibiting MAO-A, the degradation of monoamine neurotransmitters in the central nervous system is reduced, and the level of central monoamines is relatively increased, thereby improving the patient's mood and playing an antidepressant role. Therefore, it can be considered that there is a positive correlation between the MAO-A enzyme inhibition rate and the relief of mental tension and the relief of insomnia problems.

[0069] After each strain was fermented for 24 hours, the inhibitory effect of its fermentation supernatant on MAO-A enzyme was detected. Specifically, the preparation process of the lactic acid bacteria fermentation broth included: activating the strain on MRS medium for 16 hours to obtain single colonies. Inoculating at an inoculation amount of 4% (each strain was adjusted to the same viable cell number for inoculation) into 10% skim milk medium and culturing at 37 °C for 24 hours to obtain the fermentation broth. The fermentation broth was treated in a boiling water bath for 10 minutes to inactivate the bacteria and enzymes. The bacteria and coagulated proteins were removed by centrifugation, and the supernatant was used as the test sample in this example and could be freeze-dried for standby as needed.

[0070] Preparation of crude MAO enzyme: The crude MAO enzyme was extracted from the livers of old male rats. The liver tissues were rinsed with pre-cooled PBS buffer, and the connective tissues were removed and cut into pieces. Then, they were homogenized with pre-cooled 0.25 mol / L sucrose solution. Low-speed centrifugation (1000 g, 4 °C) and high-speed centrifugation (10000 g, 4 °C) were carried out successively. The supernatant and precipitate were discarded, and the middle layer was retained. The middle layer was suspended in 1.2 mol / L sucrose solution and ultra-high-speed centrifuged (53000 g, 4 °C) for 2 hours, and the precipitate was collected. The precipitate was washed with 1.15% KCl and 0.02 mol / L PBS, and finally the crude enzyme was suspended in PBS to obtain the crude enzyme solution, which was aliquoted and stored at -80 °C.

[0071] Determination of MAO activity inhibition rate: Potassium phosphate buffer, crude enzyme solution and the sample to be tested (lactic acid bacteria fermentation broth) were added to a 96-well plate and incubated at 37 °C for 5 minutes. Then, kynuramine substrate was added, and the mixture was shaken and mixed evenly. The absorbance value (A1) at 360 nm was measured using an enzyme-linked immunosorbent assay reader. After reacting at 37 °C for 60 minutes, the absorbance value (A2) at 360 nm was measured again. Blank control: The absorbance value change (A0) was measured by replacing the sample to be tested with phosphate buffer.

[0072] Calculation formula: Relative inhibition rate of MAO (%) = [1 - (A1 - A2) / A0] × 100%

[0073] The results are shown in Figure 2 , and it was found that Lactobacillus gasseri LyLG1 could effectively inhibit MAO-A enzyme.

[0074] Example 4: Experiment on the sleep-improving effect of Lactobacillus gasseri and bacteriocin composition

[0075] In this experiment, the experimental group of Lactobacillus gasseri LyLG1 used the fermented Lactobacillus gasseri LyLG1 powder, and the detected bacterial count was 3.0×10 10 CFU / g.

[0076] In this experiment, the test substance of the experimental group of bacteriocin composition was a composition including Lactobacillus gasseri and imidazole dipeptide. In this bacteriocin composition, the bacterial count of Lactobacillus gasseri LyLG1 was 1.125×10 10 CFU / g, the content of anserine was about 1.70%, and the content of carnosine was about 0.17%.

[0077] At a concentration of 500 μg / mL, the bacterial count in the experimental group of Lactobacillus gasseri LyLG1 was about 1.69×10 7 CFU / mL. Converted to the daily human intake, it was about 9.0×10 10 CFU of Lactobacillus gasseri LyLG1; the Lactobacillus gasseri LyLG1 in the experimental group of bacteriocin composition was about 5.625×10 6CFU / mL, converted to the daily human intake of Lactobacillus gasseri LyLG1: 3.4×10 10 CFU.

[0078] Wild-type AB strain zebrafish at 5 days post-fertilization (5 dpf) were randomly selected and placed in 6-well plates, with 30 zebrafish in each well (experimental group). The test samples were administered in water (concentrations are shown in Table 1). At the same time, a normal control group and a model control group were set up, and the volume per well was 3 mL. After treatment at 28°C for 1 day, except for the normal control group, pentylenetetrazol was administered in water to the remaining experimental groups to establish a zebrafish insomnia model. After continuing the treatment for 1 h, the minimum toxic concentration (MTC) of the samples on the model zebrafish was measured. Under the experimental conditions of this experiment, the MTCs of the bacteriocin composition and Lactobacillus gasseri LyLG1 for improving sleep efficacy were both 1000 μg / mL. See Table 1 for details.

[0079] Table 1. Results of the concentration exploration experiment for the sleep-improving efficacy of the samples (n = 30)

[0080]

[0081] Wild-type AB strain zebrafish at 5 dpf were randomly selected and placed in 6-well plates, with 30 zebrafish in each well (experimental group). The samples were administered in water (concentrations are shown in Table 2), and the positive control group was at a concentration of 29.0 μg / mL of oxazepam. At the same time, a normal control group and a model control group were set up, and the volume per well was 3 mL. After treatment at 28°C for 1 day, 10 zebrafish were randomly selected from each experimental group and transferred to 96-well plates, with 1 fish / 200 μL / well. Except for the normal control group, pentylenetetrazol was administered in water to the remaining experimental groups to establish a zebrafish insomnia model. The awakening activity of the zebrafish within 1 h was measured using a behavior analyzer (ZebraLab 3.22.3.31, Viewpoint, France), and the sleep-improving efficacy of the samples was evaluated based on the statistical analysis results of the above indicators. The statistical processing results were expressed as mean ± SE. Statistical analysis was performed using SPSS 26.0 software, and p < 0.05 indicated that the difference was statistically significant.

[0082] Under the experimental conditions of this experiment, the effective concentration of oxazepam was 29.0 μg / mL, corresponding to a human daily dosage of 174 mg; the bacteriocin composition and Lactobacillus gasseri LyLG1 improved sleep efficacy, specifically manifested as reducing the awakening activity of zebrafish. The bacteriocin composition and Lactobacillus gasseri LyLG1 were effective at 500 μg / mL and 1000 μg / mL respectively, corresponding to human daily dosages of 3 g and 6 g (the conclusion of the human dosage measurement conversion is only for reference, and the specific effective concentration still needs to be further verified by experiments). See Table 2 for details. Figure 3 and Figure 4 .

[0083] Table 2. Results of the evaluation experiment for the sleep-improving efficacy of the samples (n = 10)

[0084]

[0085] Compared with the model control group, **p < 0.01, ***p < 0.001

[0086] The experimental results of this example can show that: the bacteriopeptide composition can achieve an effect even better than that of the pure bacterial powder when the number of added bacteria is small.

[0087] Example 5: Experiment on the efficacy of Lactobacillus gasseri and imidodipeptide composition in inhibiting MAO-A enzyme

[0088] Experimental procedure:

[0089] 1. Preparation of experimental materials: Recombinant human MAO-A and kynuramine (kynuramine) as a substrate were used in the experiment. Reagents such as horseradish peroxidase (HRP) and Amplex Red were also used in the experiment.

[0090] 2. Preparation of enzyme reaction mixture: A reaction mixture containing 100 mM phosphate buffer (pH 7.4), 250 μM kynuramine substrate, MAO-A enzyme and the sample was reacted in the dark at 37 °C for 40 minutes.

[0091] 3. Addition of HRP and Amplex Red: After the reaction, Amplex Red (0.5 mM) and HRP (1 mg / mL) were added to the mixture and the reaction was continued for 5 minutes.

[0092] 4. Termination of reaction and detection: The reaction was terminated by adding sulfuric acid (0.5 M) to the mixture, and the absorbance at 571 nm was measured by a spectrophotometer.

[0093] Experimental results:

[0094] The inhibitory rates of each raw material of the bacteriopeptide composition and the composition on MAO-A enzyme were tested, and the relevant data are as follows. The concentration of each group in this experiment was 17.6 mg / ml.

[0095] Group 1 (bacteriopeptide composition): 37.5% Lactobacillus gasseri powder; 17% imidodipeptide composition (i.e., the aforementioned fish-derived food-grade imidodipeptide composition raw material); 22.7% cottonseed oligosaccharide; 5.7% chitosan oligosaccharide; 17% inulin;

[0096] Group 2 (inulin): 100% inulin;

[0097] Group 3 (Lactobacillus gasseri and inulin): 37.5% Lactobacillus gasseri; 62.5% inulin;

[0098] Group 4 (imidazole dipeptide composition and inulin): 17% imidazole dipeptide composition; 83% inulin;

[0099] Group 5 (Lactobacillus gasseri): 100% Lactobacillus gasseri;

[0100] Group 6 (imidazole dipeptide composition): 100% imidazole dipeptide composition (the aforementioned fish-derived food-grade imidazole dipeptide composition raw material).

[0101] Results and Discussion:

[0102] According to Figure 5 It can be found that the MAO enzyme inhibition rate of the bacteriopeptide composition at this concentration is much better than that of each raw material group. In this experiment, although the imidazole dipeptide composition itself showed a certain MAO enzyme inhibition rate, the 100% concentration of the imidazole dipeptide composition was much lower than that of Group 1 of the bacteriopeptide composition with only 17% imidazole dipeptide composition added.

[0103] In addition, it is worth noting that Lactobacillus gasseri alone has no inhibitory effect on MAO enzyme, but after being compounded with inulin, which also has no inhibitory effect on MAO enzyme, it shows a partial inhibitory effect. Combining the experimental results of the experiment on stimulating the secretion of 5-HTP by the enterochromaffin cell model with a single strain of Lactobacillus gasseri, it can be inferred that Lactobacillus gasseri itself has no inhibitory effect on MAO enzyme, but its fermentation products have an inhibitory effect on MAO enzyme. Therefore, after combining with the prebiotic inulin, the activation and cultivation speed of Lactobacillus gasseri is faster, and a certain amount of fermentation products can be produced during the reaction time of the MAO enzyme experiment, and play an inhibitory role on MAO enzyme.

[0104] In the group of single Lactobacillus gasseri, the activation and cultivation process could not be completed within the experimental reaction time, and no fermentation products were produced. In the experiment in PART A of this article, although it was a single Lactobacillus gasseri, due to the experimental process of inoculating and fermenting for 24 hours and then taking the supernatant for the MAO enzyme inhibition rate test, there was also a certain inhibition rate.

[0105] This comparison before and after can also prove that the bacteriopeptide composition can accelerate the activation and fermentation of the bacterial powder, and it is speculated that it can make the bacteria take effect faster in the body.

[0106] The above embodiments are only used to illustrate the present invention, rather than to limit the present invention. Without departing from the essence and scope of the present invention, those skilled in the art can also make various changes and modifications to achieve the same purpose. Therefore, all equivalent technical solutions also belong to the protection scope of the present invention.

Claims

1. A Lactobacillus gasseri having a deposit number of CCTCC NO: M20241476.

2. A bacterial preparation comprising the Lactobacillus gasseri according to claim 1.

3. The bacterial preparation according to claim 2, which is a liquid or solid preparation in the form of live bacteria or inactivated bacteria; Preferably, the live bacteria concentration of the solid preparation of live bacteria is 5×10 11 Up to 4×10 12 CFU / g, the concentration of live bacteria in liquid preparations is 5×10 11 Up to 4×10 12 CFU / mL.

4. A postbiotic, which is a postbiotic containing bacteria and metabolites obtained by fermenting the Lactobacillus gasseri according to claim 1 or the bacterial preparation according to claim 2 or 3 in a culture medium, or a postbiotic containing a fermentation product; Preferably, the culture medium is MRS medium or peptone medium; More preferably, the fermentation product obtained by fermenting and culturing the Lactobacillus gasseri described in claim 1 in a culture medium is a postbiotic containing bacteria and metabolites; or, the fermentation product is further centrifuged to collect the supernatant of the fermentation liquid, and filtered with a filter membrane to obtain the postbiotic containing metabolites from which the bacteria are removed; optionally, the postbiotic can be further dried to prepare a powder.

5. A composition comprising the Lactobacillus gasseri according to claim 1, the bacterial preparation according to claim 2 or 3, or the postbiotic according to claim 4, and further comprising imidazole dipeptide.

6. The composition according to claim 5, wherein The ratio of Lactobacillus gasseri or bacterial preparation or postbiotic to imidazole dipeptide is 2-3 parts by weight of Lactobacillus gasseri: 0.05-0.6 parts by weight of imidazole dipeptide; Preferably, the imidazole dipeptide comprises anserine and carnosine; further preferably, the ratio of anserine to carnosine is 5-40:0.5-20.

7. Use of the Lactobacillus gasseri according to claim 1, the bacterial preparation according to claim 2 or 3, the postbiotic according to claim 4, or the composition according to claim 5 in the preparation of food and / or food additives.

8. The use according to claim 7, wherein: The food is one or more of a powdered solid beverage, a liquid beverage, a jelly, a compressed candy, a yogurt, a baked food, and a capsule; Preferably, the food is a health food.

9. The use according to claim 7, wherein: The food has the effects of improving sleep and / or relieving nervous tension.

10. Use of the Lactobacillus gasseri according to claim 1, the bacterial preparation according to claim 2 or 3, the postbiotic according to claim 4, or the composition according to claim 5 in the preparation of a preparation for stimulating enterochromaffin cells to produce 5-HTP.

11. Use of the Lactobacillus gasseri according to claim 1, the bacterial preparation according to claim 2 or 3, the postbiotic according to claim 4, or the composition according to claim 5 in the preparation of an MAO-A enzyme inhibitor.

Images